



Shantani Proteome Analytics Press Release

Shantani Proteome Analytics Pvt. Ltd. collaborates with Dualsystems Biotech AG to partner business development activities for the two companies.

Pune, India, Feb 2016: - Shantani Proteome Analytics Pvt. Ltd has announced today that it will partner with Dualsystems Biotech AG to support each other in business development.

The partnership will combine the complementary strengths of Shantani, a leading service provider for target deconvolution of small molecules with the strengths of Dualsystems a leading service providing company for target deconvolution of large molecules.

Shantani provides customized target identification solutions utilizing both traditional and novel chemical-proteomics based technologies. The advanced portfolio of technologies includes proprietary - Unique Polymer Technology (UPT) that utilizes specifically designed affinity matrix to immobilize the small molecule without any need of its derivatization and Sub Cellular Location Specific Target Capture Technology (SCLS) that utilizes sub-cellular location specific peptide probes to capture targets from specific cellular location. These technologies can achieve false positive target identification rates as low as 20%. Shantani's technologies provides an unbiased approach to identify few yet 'rightful' targets of small molecule that eventually adds in lead optimization, lead selectivity/toxicity profiling and understanding action mechanism of the small molecule.

Dualsystems provides the ligand-receptor capture (LRC-TriCEPS) technology developed by Prof. Bernd Wollscheid and licensed in from the ETHZ. The LC-MS/MS based technique is the only technology worldwide to identify the unknown receptors of a ligand on the living cells. The LRC-TriCEPS Technology uses a proprietary tri functional crosslinker molecule called TriCEPSTM to identify targets for large molecules (biotherapeutics/biologics) located in the cell membrane. The technology is able to identify the targets of peptides, proteins, antibodies and viruses while the target cell is still alive during ligand-target interaction. Next to the main targets, the technology will also identify off targets and therefore provides crucial information for selecting the right drug candidate.

Contact for Shantani:

Shantani Proteome Analytics Pvt. Ltd.
Dr. Chaitanya Saxena
Tel: +91 20 6410 3918
Website: www.shantani.com
Email: info@shantani.com

Contact for Dualsystems:

Dualsystems Biotech AG
Dr. Paul Helbling
Tel: +41 44 738 50 00
Website: www.dualsystems.com
Email: info@dualsystems.com